Nguyen
01-05-2021, 03:24 PM
For some reason I can not post in "Articles of interest" section.
https://www.targetedonc.com/view/fda-grants-fast-track-designation-for-her2-positive-metastatic-breast-cancer?utm_source=sfmc&utm_medium=email&utm_campaign=1-5-21_TTE_Daily%20eNews_Unsponsored&eKey=RGFkYUFrYUF1c3RpbkRhZEBnbWFpbC5jb20=
http://ambrx.com/ambrx-presents-phase-1-trial-data-update-and-phase-23-clinical-trial-in-progress-for-lead-program-arx788-at-the-2020-san-antonio-breast-cancer-symposium/
ARX788, a Site-specific anti-HER2 Antibody Drug Conjugate, Demonstrates Potent and Selective Activity in HER2 Low and T-DM1 Resistant Breast and Gastric Cancers
https://sci-hub.se/https://mct.aacrjournals.org/content/19/9/1833.full-text.pdf
https://www.targetedonc.com/view/fda-grants-fast-track-designation-for-her2-positive-metastatic-breast-cancer?utm_source=sfmc&utm_medium=email&utm_campaign=1-5-21_TTE_Daily%20eNews_Unsponsored&eKey=RGFkYUFrYUF1c3RpbkRhZEBnbWFpbC5jb20=
http://ambrx.com/ambrx-presents-phase-1-trial-data-update-and-phase-23-clinical-trial-in-progress-for-lead-program-arx788-at-the-2020-san-antonio-breast-cancer-symposium/
ARX788, a Site-specific anti-HER2 Antibody Drug Conjugate, Demonstrates Potent and Selective Activity in HER2 Low and T-DM1 Resistant Breast and Gastric Cancers
https://sci-hub.se/https://mct.aacrjournals.org/content/19/9/1833.full-text.pdf